WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406104
Description: JH295 is an irreversible, cysteine-targeted inhibitors of the human centrosomal kinase, Nek2. JH295 irreversibly inhibited cellular Nek2 without affecting the mitotic kinases, Cdk1, Aurora B, or Plk1. Moreover, JH295 did not perturb bipolar spindle assembly or the spindle assembly checkpoint. JH295 is the first small molecule shown to inactivate Nek2 kinase activity in cells.
MedKoo Cat#: 406104
Chemical Formula: C18H16N4O2
Exact Mass: 320.12733
Molecular Weight: 320.35
Elemental Analysis: C, 67.49; H, 5.03; N, 17.49; O, 9.99
Synonym: JH295; JH 295; JH-295
IUPAC/Chemical Name: (Z)-N-(3-((2-ethyl-4-methyl-1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)propiolamide
InChi Key: ORKOHXAJFGRZCL-LCYFTJDESA-N
InChi Code: InChI=1S/C18H16N4O2/c1-4-16-19-10(3)15(21-16)9-13-12-8-11(20-17(23)5-2)6-7-14(12)22-18(13)24/h2,6-9H,4H2,1,3H3,(H,19,21)(H,20,23)(H,22,24)/b13-9-
SMILES Code: C#CC(NC1=CC2=C(NC(/C2=C\C3=C(C)N=C(CC)N3)=O)C=C1)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 320.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Grant PK, Dalchau N, Brown JR, Federici F, Rudge TJ, Yordanov B, Patange O,
Phillips A, Haseloff J. Orthogonal intercellular signaling for programmed spatial
behavior. Mol Syst Biol. 2016 Jan 25;12(1):849. doi: 10.15252/msb.20156590.
PubMed PMID: 26814193; PubMed Central PMCID: PMC4731010.
2: Boehm CR, Ueda M, Nishimura Y, Shikanai T, Haseloff J. A Cyan Fluorescent
Reporter Expressed from the Chloroplast Genome of Marchantia polymorpha. Plant
Cell Physiol. 2016 Feb;57(2):291-9. doi: 10.1093/pcp/pcv160. Epub 2015 Dec 3.
PubMed PMID: 26634291; PubMed Central PMCID: PMC4788411.
3: Henise JC, Taunton J. Irreversible Nek2 kinase inhibitors with cellular
activity. J Med Chem. 2011 Jun 23;54(12):4133-46. doi: 10.1021/jm200222m. Epub
2011 May 31. PubMed PMID: 21627121; PubMed Central PMCID: PMC3663048.
4: Haseloff J. Old botanical techniques for new microscopes. Biotechniques. 2003
Jun;34(6):1174-8, 1180, 1182. PubMed PMID: 12813885.
NEK2 (NIMA-related expressed kinase 2) is a serine/threonine centrosomal kinase that acts as a critical regulator of centrosome structure and function. Aberrant NEK2 activities lead to failure in regulating centrosome duplication. NEK2 overexpression promotes tumorigenesis and is associated with poor prognosis in several cancers. Increased NEK2 expression during the late pathological stage has been detected in the Oncomine liver dataset and hepatocellular carcinoma (HCC) specimens. Elevated NEK2 protein is associated with poor overall survival in patients with HCC. However, the precise roles and mechanisms of NEK2 in liver cancer progression remain largely unknown. An earlier functional study revealed that NEK2 mediates drug resistance (cisplatin or lipo-doxorubicin) via expression of an ABCC10 transporter. Active angiogenesis and metastasis underlie the rapid recurrence and poor survival of HCC. Results from the current study showed that NEK2 mediates tumor growth, metastasis and angiogenesis in vivo. NEK2-mediated drug resistance was blocked by a specific PI3K or AKT inhibitor. Moreover, NEK2 mediated liver cancer cell migration via pAKT/NF-κB signaling and matrix metalloproteinase (MMP) activation. Angiogenesis was induced via the same signaling pathway and IL-8 stimulation. Our findings collectively indicate that NEK2 modulates hepatoma cell functions, including growth, drug resistance, metastasis and angiogenesis via downstream genes activation.